絞り込み

オススメ書籍

15605

RSS

お知らせ

全て読む

広告

ファンケルが予防医療を事業化 遺伝子検査を利用、サプリや食事指導 - 産経ニュース

ファンケルが予防医療を事業化 遺伝子検査を利用、サプリや食事指導産経ニュースファンケルヘルスサイエンスは21日、遺伝子検査を利用した予防医療事業を始めると発表し...

  1. 経産相、再稼働で難しい役回りも 核のごみ...
  2. NHK NEWS WEB 子どもの味覚に...
  3. 脆弱な埼玉の救急医療、ER病院など整備を...
  4. エアロスミスのジョーイ・クレイマー、重病...

ニュース一覧

Selective Identification of Hedgehog Pathway Antagonists By Direct Analysis of Smoothened Ciliary Translocation.

著者 Wang Y , Arvanites AC , Davidow L , Blanchard J , Lam K , Yoo JW , Coy S , Rubin LL , McMahon AP
ACS Chem Biol.2012 May 3 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Stem Cell and Regenerative Biology, ‡Department of Molecular and Cellular Biology, §Harvard Stem Cell Institute, ∥Department of Chemistry and Chemical Biology, and ⊥Harvard College, Harvard University , Cambridge, Massachusetts 02138, United

スターを付ける スターを付ける     (45view , 0users)
  • このエントリーをはてなブックマークに追加

Full Text Sources

Hedgehog (Hh) signaling promotes tumorigenesis. The accumulation of the membrane protein Smoothened (Smo) within the primary cilium (PC) is a key event in Hh signal transduction, and many pharmacological inhibitors identified to date target Smo's actions. Smo ciliary translocation is inhibited by some pathway antagonists, while others promote ciliary accumulation, an outcome that can lead to a hypersensitive state on renewal of Hh signaling. To identify novel inhibitory compounds acting on the critical mechanistic transition of Smo accumulation, we established a high content screen to directly analyze Smo ciliary translocation. Screening thousands of compounds from annotated libraries of approved drugs and other agents, we identified several new classes of compounds that block Sonic hedgehog-driven Smo localization within the PC. Selective analysis was conducted on two classes of Smo antagonists. One of these, DY131, appears to inhibit Smo signaling through a common binding site shared by previously reported Smo agonists and antagonists. Antagonism by this class of compound is competed by high doses of Smo-binding agonists such as SAG and impaired by a mutation that generates a ligand-independent, oncogenic form of Smo (SmoM2). In contrast, a second antagonist of Smo accumulation within the PC, SMANT, was less sensitive to SAG-mediated competition and inhibited SmoM2 at concentrations similar to those that inhibit wild-type Smo. Our observations identify important differences among Hh antagonists and the potential for development of novel therapeutic approaches against mutant forms of Smo that are resistant to current therapeutic strategies.
PMID: 22554036 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード